From GWAS to NBAS
At ASCO '11, Targeting Successes Spur Next-Generation Approaches
By Anette Breindl
Monday, June 6, 2011
CHICAGO The 47th annual meeting of the American Society for Clinical Oncology began with something of an ode to targeted therapy. In data presented in a session on personalized medicine, researchers from the University of Texas MD Anderson Cancer Center showed that when end-stage cancer patients had their tumors analyzed and received targeted therapies that matched their mutations, the response rate more than quintupled and survival increased by several months.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.